THX Pharma Publishes its First Half 2026 Results

THX Pharma, formerly Theranexus, announces its financial results for the first half of 2026, marking a key milestone in the treatment of rare neurological diseases. The company reported significant revenue of €3,239,000, driven by a strategic agreement with Biocodex. This agreement secured funding for the development of Batten-1 and strengthened TX01, involving high-level partnerships with Biocodex and Exeltis.

The results show a reduced half-year loss of €100,000, compared to €1,072,000 the previous year, and a strong cash position of €17.5 million. The Phase 3 clinical trial for Batten-1 is being launched, with applications for authorization submitted to the main health authorities. The board of directors approved these results, thus demonstrating THX Pharma's restored financial stability.